Announcements

Hello –

You are invited to participate in this research project “A Survey of Anticoagulant (Warfarin & LMWH) Periprocedural Management for Those with Mechanical Heart Valves” (Pro0016149). Your participation is greatly appreciated, please click on the following link to complete the survey: https://redcap.link/periopmechanicalvalves 

The survey will take ~ 10 minutes to complete. 

Thank you for your consideration. If you have questions, please contact Dr. Tammy Bungard at tammy.bungard@ualberta.ca.

Co-Investigators: Dr. Ava Azhir, Dr. Cynthia Brocklebank, Dr. James Douketis, Dr. Darcy Lamb, Dr. Jennifer Lowerison, Dr. Peter Thomson

Dear colleagues,

The ISTH SSC on Fibrinogen and FXIII is launching an international cohort study on afibrinogenemia, focusing on rare but clinically significant complications, particularly thrombosis.

Afibrinogenemia is an ultra-rare disorder with highly variable clinical expression. While bleeding manifestations are well recognized, thrombotic events remain insufficiently characterized and poorly understood. This study aims to collect standardized clinical data to better define the frequency, triggers, management, and outcomes of thrombotic and severe bleeding complications.

The survey is concise and takes only a few minutes per patient. No protected health information should be included.

We warmly invite colleagues caring for patients with confirmed afibrinogenemia to contribute cases and support this collaborative international effort.

Thank you for your participation.

For additional information, please contact Alessandro.casini@hug.ch

Dear Health Care Practitioner,

Background

The peri-procedural management of direct oral anticoagulants (DOACs) in persons with cancer (PWC) undergoing tunneled or port central venous catheter (CVC) insertion is a common but understudied clinical problem, with conflicting management advice from guidelines and resultant uncertainty for best practices. Data from prospective studies assessing peri-procedural DOAC management exist; however, these data pertain to procedures in the general population. These management strategies may not be applicable to PWC because (1) although CVC insertion is a low risk, image-guided specialized procedure, (2) PWC are at considerably higher risk of peri-procedural bleeding and thrombosis than non-PWC. It is not surprising, therefore, that guideline recommendations and current practices vary widely. We propose a survey of health care practitioners to gauge their practices and comfort regarding peri-procedural DOAC management for CVC insertion in PWC.

We are designing an investigator initiated randomized controlled trial comparing continued to interrupted DOAC for CVC insertion in PWC. We are asking for your input through this survey to better understand current practices of peri-procedural DOAC management for CVC insertion in PWC and help guide trial design.

You are invited to take part in this study survey because you are a health care practitioner that is involved in peri-procedural anticoagulation and/or CVC insertion. 

Survey

This study will look at your current practices of peri-procedural DOAC management for CVC insertion in PWC and your thoughts on a clinical trial comparing continued to interrupted DOAC for CVC insertion in PWC. The aim of this research is to gain insight into current practices and help design a clinical trial.

Your participation in this survey is completely voluntary.

If you agree to participate, you will be asked to complete an online survey. The survey is 14 to 18 questions long, and is estimated to take no longer than 10 minutes to complete. The survey includes questions about:

·       your professional background information such as your profession and type of practice

·       your practice of peri-procedural DOAC management for CVC insertion in PWC

·       your opinions on a clinical trial comparing continued to interrupted DOAC for CVC insertion in PWC

Your responses will be submitted anonymously through the survey, and no personal data will be collected.

There are no anticipated risks in participating in this study.

While there is no direct benefit to you, your input will help inform the design of an important clinical trial in cancer-related anticoagulation. 

Participants will not be named or identified in any study reports, publications, or presentations that may come from this study. Also, once the data is collected we will not be able to withdraw the data from the study.

You will not be paid for taking part in this study. 

Questions

If you have any questions, concerns or would like to speak to the study team for any reason, please contact Jameel Abdulrehman at Jameel.Abdulrehman@uhn.ca.

Please note that communication via e-mail is not absolutely secure. Thus, please do not communicate personal sensitive information via e-mail. 

If you have any questions about your rights as a research participant or have concerns about this study, call the Chair of the University Health Network Research Ethics Board (UHN REB) or the Research Ethics office number at 416-581-7849. The REB is a group of people who oversee the ethical conduct of research studies. The UHN REB is not part of the study team. Everything that you discuss will be kept confidential. 

By completing and submitting this online survey, you consent to participate in this study and your responses will be used solely for research purposes.

Thank you for your help with this endeavor.

Jameel Abdulrehman, MD, MSc, FRCPC, University of Toronto  

Joseph Shaw, MD, MSc, FRCPC, DRCPSC
University of Ottawa

Steffan Stella, MD, ScD, McMaster University

Sebastian Mafeld, MBBS, FRCR, University of Toronto

James Douketis, MD, FRCPC, McMaster University 

Rita Selby, MBBS, FRCPC, MSc, University of Toronto

Peter Gross, MD, MSc, FRCPC, University of Toronto                                           

Marc Carrier, MD, MSc, FRCPC, University of Ottawa

Dear colleagues,

Chimeric antigen receptor (CAR) T-cell therapy has significantly improved outcomes in patients with relapsed/refractory aggressive large B-cell lymphoma (R/R LBCL) and R/R multiple myeloma, and is rapidly being introduced to other disease fields. 

Thrombosis and bleeding complications are increasingly reported in patients undergoing CAR T-cell therapy, affecting an estimated 10–20% of patients. However, their incidence and risk factors remain unclear, also due to heterogeneity between reporting studies and missing data, causing these complications to remain under-recognized and poorly understood.

Current supportive care practices are largely extrapolated from stem cell transplant populations, despite CAR T-cell therapy’s distinct pathophysiology, and there is no consensus on optimal monitoring intervals, transfusion thresholds, or preventive interventions. 

Hence, to gain a better understanding of current practices in supportive care management for CAR T-cell patients, particularly in the hemostasis-related monitoring and supportive care, as well as how complications of thrombosis and bleeding in patients receiving CAR T-cell therapy are documented, we please ask you to complete the following survey: https://redcap.link/support_CART

Please feel free to distribute this survey among colleagues involved in CAR T-cell therapy, hemostasis and thrombosis, and/or transfusion medicine.

Thank you in advance for your contributions and collaboration.

On behalf of the ISTH SSC Cancer-associated thrombosis and hemostasis and EHA SWG on Transfusion,

Mandy Lauw, Darko Antic, Lizzie Jutchinson, Kirsty Sharplin, Simon Stanworth

Dear participant,

This survey addresses current issues and challenges related to blood-contacting medical devices, assessing methodologies for the experimental evaluation of blood-contacting biomaterials under flow conditions. The aim is to develop robust, evidence-based standards that will support improved biomaterials and device design and accelerate safe and effective clinical translation.

Your contributions are essential for advancing our collective understanding of medical device-associated thrombosis and informing best practices in thrombogenicity testing that will strengthen innovation and patient outcomes across the field.

Survey link: https://redcap.isth.org/surveys/?s=RECEKKNLWEJNYARA

Per the Guidelines and Guidance (G&G) Committee process for guidance manuscripts, draft manuscripts go through a public comment period and G&G Committee review and approval before submitting the manuscript to the Journal of Thrombosis and Haemostasis (JTH).

The G&G Committee would like to announce that the guidance manuscript titled, " The Diagnosis and Evaluation of Women and Girls with Hemophilia and Hemophilia Carriers: Guidance from the SSC of the ISTH," is now open for public comment. Note: This manuscript is confidential and in draft form.

Please click here to submit your comments by Thursday, February 19, 2026.

Per the Guidelines and Guidance (G&G) Committee process for guidance manuscripts, draft manuscripts go through a public comment period and G&G Committee review and approval before submitting the manuscript to the Journal of Thrombosis and Haemostasis (JTH).

The G&G Committee would like to announce that the guidance manuscript titled, " The Diagnosis and Evaluation of Women and Girls with Hemophilia and Hemophilia Carriers: Guidance from the SSC of the ISTH," is now open for public comment. Note: This manuscript is confidential and in draft form.

Please click here to submit your comments by Thursday, February 19, 2026.

Per the Guidelines and Guidance (G&G) Committee process for guidance manuscripts, draft manuscripts go through a public comment period and G&G Committee review and approval before submitting the manuscript to the Journal of Thrombosis and Haemostasis (JTH).

The G&G Committee would like to announce that the guidance manuscript titled, " The Diagnosis and Evaluation of Women and Girls with Hemophilia and Hemophilia Carriers: Guidance from the SSC of the ISTH," is now open for public comment. Note: This manuscript is confidential and in draft form.

Please click here to submit your comments by Thursday, February 19, 2026.

Per the Guidelines and Guidance (G&G) Committee process for guidance manuscripts, draft manuscripts go through a public comment period and G&G Committee review and approval before submitting the manuscript to the Journal of Thrombosis and Haemostasis (JTH).

The G&G Committee would like to announce that the guidance manuscript titled, " Management of Thrombotic Risk Associated with Endocrine and Other Systemic Therapy in Patients with Breast Cancer: Guidance from the SSC of the ISTH," is now open for public comment. Note: This manuscript is confidential and in draft form.

Please click here to submit your comments by Thursday, February 19, 2026.

Save the Date:

An Educational Day on Pediatric Hemostasis and Thrombotic Disorders will be held on Friday, July 10, 2026, ahead of the ISTH Annual Congress in Paris. Additional details regarding the venue and agenda will be shared in due course.

This educational initiative is being conducted in coordination with the French Society on Thrombosis and Hemostasis(Club des Pédiatres en Hémostase – Société Française de Thrombose et d'Hémostase [SFTH]), the International Pediatric Thrombosis Network (IPTN), and the Pediatric and Neonatal Subcommittee of the SSC of the ISTH. The program will focus on contemporary topics in pediatric bleeding and thrombotic disorders and is intentionally designed to complement, and not duplicate, the Pediatric/Neonatal SSC scientific session.

We look forward to your future participation.

With best regards,
Madhvi

Dear Colleagues,

On behalf of the Hemostasis Working Party of the Pediatric/Neonatal Thrombosis and Haemostasis Subcommittee, we are pleased to invite your center to participate in a collaborative research initiative entitled “International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR).” This study has been approved by the International Society on Thrombosis and Haemostasis.

Patients with congenital bleeding disorders are at increased risk of bleeding complications during dengue virus infection due to thrombocytopenia, platelet dysfunction, vascular leakage, and coagulopathy. Despite the clinical importance of this issue, there is currently a lack of comprehensive international registry data addressing bleeding manifestations, management strategies, and outcomes in this vulnerable population.

The primary objective of this study is to evaluate bleeding complications, management approaches, clinical outcomes, and associated complications in patients with congenital bleeding disorders—such as hemophilia, von Willebrand disease, and platelet disorders—who are affected by dengue infection. Your participation would make a valuable contribution to improving the understanding and management of bleeding in this clinical context.

 To facilitate data collection, the study group has developed a REDCap-based electronic data capture system for patient registration. The full study proposal in English is available upon request for centers interested in participating.

Should you require further information or wish to express interest in joining this international registry, please contact Nongnuch.sir@mahidol.ac.th. or fill in your contact information https://docs.google.com/forms/d/e/1FAIpQLSdY8BM1O5nTQHJoSuW-Knm_EXBSaer5oh34JuuSNhLTqvrSUw/viewform?usp=header

We would be honored to collaborate with your institution on this important initiative.

Yours sincerely,

Nongnuch Sirachainan MD

On behalf of the Hemostasis Working Party

Pediatric/Neonatal Thrombosis and Haemostasis Subcommittee

Per the Guidelines and Guidance (G&G) Committee process for guidance manuscripts, draft manuscripts go through a public comment period and G&G Committee review and approval before submitting the manuscript to the Journal of Thrombosis and Haemostasis (JTH).

The G&G Committee would like to announce that the guidance manuscript titled, "Management of anticoagulation in patients with heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass: Guidance from the ISTH SSC on Perioperative and Critical Care Haemostasis and Thrombosis," is now open for public comment. Note: This manuscript is confidential and in draft form.

Please click here to submit your comments by Wednesday, November 12, 2025.

Per the Guidelines and Guidance (G&G) Committee process for guidance manuscripts, draft manuscripts have to go through a public comment period and Committee review and approval before submitting the manuscript to the Journal of Thrombosis and Haemostasis (JTH).

The G&G Committee would like to announce that the guidance manuscript titled, "Development of New Antithrombotic Drugs for Children (Part 1): Guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group," is now open for public comment. Note: This manuscript is confidential and in draft form.

Please click here for a link to the guidance and to submit your comments by Thursday, October 30, 2025.

Dear colleagues:

As part of the "Assessment of methods of documentation & reporting of ABR in clinical trials" project, we have drafted recommendations for standardizing ABR.

We now invite you to collect feedback of the proposed standardization from your communities, and to submit your comments over the upcoming month.

Please submit any comments to Alok Srivastava at asriv@haematology.in or respond directly to the discussion board post in the myISTH community forum.

Dear Colleagues,

You are invited to participate in a research survey titled "SCOPE TXA: Sickle Cell Observations of Provider Experiences with Tranexamic Acid." This study is being conducted by researchers at Central Michigan University and the Children's Hospital of Michigan. The purpose of this survey is to gather insights from providers across various specialties who care for patients with sickle cell disease. We are particularly interested in understanding the clinical scenarios in which tranexamic acid (TXA) has been used, how dosing is managed, and any considerations or hesitations providers may have regarding its use in this unique patient population.

Even if you have not personally used TXA in patients with sickle cell disease, we are still very interested in your perspectives on the potential use of this medication in relevant clinical situations.

Key details:

· Estimated time to complete: 5–10 minutes

· Confidentiality: Responses will remain confidential

· Voluntary Participation: Participation is entirely voluntary and anonymous

· IRB Approval: Central Michigan University IRB has approved this study

· Compensation: Participants who complete the survey may choose to enter a drawing to win one of ten $50.00 gift cards. Gift cards will be delivered via mail.

Your insights will help inform future clinical guidance and promote safe, evidence-informed care for individuals living with sickle cell disease.

Please only complete the survey once, even if you receive it through multiple channels.

https://redcap.cmich.edu/surveys/?s=7MFD9LP7FAKPXPAX

If you have any questions, please do not hesitate to contact the principal investigator, Dr. Gianna Guzzardo Valenti, at Valen4g@cmich.edu or (313) 745-5515.

Thank you for your time and valuable input. You can find more information about the study here:  SCOPE TXA_Research Information Sheet.docx

Sincerely,

Gianna Guzzardo Valenti, MD

Children's Hospital of Michigan

Dear Colleagues,

You are invited to participate in a research survey titled "SCOPE TXA: Sickle Cell Observations of Provider Experiences with Tranexamic Acid." This study is being conducted by researchers at Central Michigan University and the Children's Hospital of Michigan. The purpose of this survey is to gather insights from providers across various specialties who care for patients with sickle cell disease. We are particularly interested in understanding the clinical scenarios in which tranexamic acid (TXA) has been used, how dosing is managed, and any considerations or hesitations providers may have regarding its use in this unique patient population.

Even if you have not personally used TXA in patients with sickle cell disease, we are still very interested in your perspectives on the potential use of this medication in relevant clinical situations.

Key details:

· Estimated time to complete: 5–10 minutes

· Confidentiality: Responses will remain confidential

· Voluntary Participation: Participation is entirely voluntary and anonymous

· IRB Approval: Central Michigan University IRB has approved this study

· Compensation: Participants who complete the survey may choose to enter a drawing to win one of ten $50.00 gift cards. Gift cards will be delivered via mail.

Your insights will help inform future clinical guidance and promote safe, evidence-informed care for individuals living with sickle cell disease.

Please only complete the survey once, even if you receive it through multiple channels.

https://redcap.cmich.edu/surveys/?s=7MFD9LP7FAKPXPAX

If you have any questions, please do not hesitate to contact the principal investigator, Dr. Gianna Guzzardo Valenti, at Valen4g@cmich.edu or (313) 745-5515.

Thank you for your time and valuable input. You can find more information about the study here:  SCOPE TXA_Research Information Sheet.docx

Sincerely,

Gianna Guzzardo Valenti, MD

Children's Hospital of Michigan

The ISTH would like to invite members to submit any comments for the draft guidance on the Surgical and Procedural Bleed Risk Stratification: Guidance for Anticoagulated Patients Undergoing Planned Surgery. 

The manuscript is confidential and in draft form and should not be forwarded.

Please click here to submit your comments by Monday, September 1, 2025.

Kindly email Andrea Hickman at andrea_hickman@isth.org if you have any questions or concerns.

We are writing to invite your institution to participate in a multicenter retrospective cohort study titled:

"PAUSE CAT" [Perioperative Anticoagulation Use and Suspension Evaluation in Cancer-Associated Thrombosis]

This collaborative project aims to better understand thrombotic and bleeding outcomes in patients with newly diagnosed cancer-associated thrombosis undergoing procedures requiring temporary anticoagulation interruption.

Study Highlights:

Design: Retrospective chart review via EMR
Inclusion: Adults with active malignancy and new VTE undergoing a procedure within 30 days of VTE diagnosis
Outcomes: Recurrent VTE, embolic events, bleeding complications, and mortality within 6 months
Data Collection: Standardized REDCap form
Site Requirements: Local IRB approval and data use agreement

This study represents a valuable opportunity to advance our understanding of real-world anticoagulation complications in high-risk oncology populations, and we hope to include a diverse cohort of institutions.

If your team is interested in participating or would like more information, please don’t hesitate to reach out. We would be happy to set up a meeting to discuss logistics and next steps.

Avi Leader

Memorial Sloan Kettering Cancer Center

leadera@mskcc.org

Rushad Patell

Beth Israel Deaconess Medical

Centerrpatell@bidmc.harvard.edu

Greetings, esteemed doctors and scientists. Your participation in the Standardization of Laboratory Assays to Measure FXII/FXIIa survey is being requested.

This survey aims to collect information across SSC members on FXII methodology with the goal of optimizing and streamlining the best practices to measure FXII zymogen and protease levels. The survey's specific aims include:

• Create a database to evaluate current practice in research involving FXII among researchers in the field of thrombosis and hemostasis.
• Conduct exploratory and validation assays to harmonize FXII measurements.
• Establish consensus guidance on the design and execution of laboratory tests to measure FXII antigen and activity.

Your participation is greatly appreciated. 

You may open the survey in your web browser by clicking the link below:
SSC Project - Standardization of laboratory assays to measure FXII antigen and activity.

If the link above does not work, try copying the link below into your web browser:
https://redcap.isth.org/surveys/?s=FRJF7L37F7KDXPR7

Greetings: we are inviting clinicians to participate in an electronic survey on global perioperative anticoagulation management practices. The survey will take approximately 15 minutes to complete.

It is hoped that any research output will benefit the standardisation of perioperative anticoagulation management and promote the uptake of Anticoagulation Stewardship internationally.

You will not need to have experience with Antithrombotic Stewardship or Anticoagulation Stewardship to complete the survey.

If you wish to participate in the survey or find out more information, please click here.

We are also contactable anytime via email should you require any further information at: julianne.chong@health.nsw.gov.au.

The ISTH would like to invite members to submit any comments for the draft guidance on the management of women with type 2B von Willebrand Disease during pregnancy and postpartum. 

The manuscript is confidential and in draft form and should not be forwarded.

Please click here to submit your comments by Monday, June 30, 2025.

Kindly email Andrea Hickman at andrea_hickman@isth.org if you have any questions or concerns.

The ISTH would like to invite members to submit any comments for the draft guidance on the management of women with type 2B von Willebrand Disease during pregnancy and postpartum. 

The manuscript is confidential and in draft form and should not be forwarded.

Please click here to submit your comments by Monday, June 30, 2025.

Kindly email Andrea Hickman at andrea_hickman@isth.org if you have any questions or concerns.

Dear Colleague,

We invite you to participate in this international survey aimed at assessing the current state of joint ultrasound practice in hemophilia care worldwide. This initiative is part of an ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders project: Standardization of musculoskeletal ultrasound in hemophilia and related disorders.

By collecting data on clinical usage patterns, professional roles, access to equipment, training levels, and perceived barriers, the study seeks to identify unmet needs across diverse healthcare settings.

The findings will help lay the foundation for future collaborative efforts to improve access to training and to support the standardized, evidence-based use of ultrasound in hemophilia management globally.

All healthcare professionals involved in hemophilia care at the treatment center - including physicians, physical therapists, and allied health professionals - are invited to complete the survey, regardless of whether joint ultrasound is currently used at their center. Gathering input from a range of professional roles will help capture multiple perspectives on the use of musculoskeletal ultrasound, reflecting the multidisciplinary nature of hemophilia care. Your insights, whether based on direct experience or lack of access, are equally important in shaping future clinical and educational strategies.

Thank you for contributing to this important initiative.

Arterial thrombosis (acute coronary syndrome or stroke) in Glanzmann Thrombasthenia (GT) patients poses a major clinical challenge. These rare but serious events are extremely difficult to manage, given the inherent bleeding risk in GT and the absence of evidence-based therapeutic guidelines. Available data are limited to a few case reports, and the heterogeneity of hemostatic strategies highlights the urgent need for standardized recommendations.

To address this gap, the GlanzArter project aims to retrospectively analyze an international cohort of adult GT patients who have experienced an arterial thrombotic event, including acute coronary syndrome or stroke. The study will describe patients' demographic and biological characteristics, cardiovascular risk factors, diagnostic procedures, hemostatic and interventional management, and outcomes, including bleeding complications. This is an official collaborative project of the ISTH SSC Subcommittee on Platelet Physiology.

The ultimate goal is to identify critical patterns and management strategies that may inform future guidelines for the care of GT patients facing arterial thrombotic events.

We are conducting a retrospective data collection through two structured CRFs (one for acute coronary syndrome, one for stroke). These have been developed by an expert panel in hemostasis, cardiology, and neurology. All data will be pseudonymized and stored in a secured database hosted by Marseille University Hospital (France).

We are now inviting all centers involved in the care of GT patients worldwide to contribute by reporting any case of stroke, transient ischemic attack, acute coronary syndrome, or unstable angina in adult GT patients. Even a single case per center is highly valuable due to the rarity of the condition.

Your participation is essential to help improve the care of these vulnerable patients.

To receive the protocol and CRFs, as well as further information please contact Prof. Paul Saultier (paul.saultier@ap-hm.fr). (See full project description under "Current Projects" on the ISTH website.)

The ISTH would like to invite members to submit any comments for the draft recommendations of the focused update of the treatment of thrombotic thrombocytopenic purpura (TTP) guidelines. 

These draft recommendations are confidential and in draft form and should not be forwarded.

Please click here to submit your comments by Wednesday, March 19, 2025.

Kindly email Andrea Hickman at andrea_hickman@isth.org if you have any questions or concerns.